Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Research Rheum

Study Probes Corticosteroid Dependence in Polymyalgia Rheumatica

Vivekanand Tiwari, MD, Emily Campbell, MD, Joshua Skydel, MD, Bryan Savage, MD, Monica Dimambro, Todd MacKenzie, PhD, & William F. Rigby, MD  |  January 24, 2024

Background/Purpose Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies have shown that patients with PMR are exposed to years of corticosteroid treatment.1,2 In a single academic center cohort, we found that 76% of patients remained on steroids at the end of two years.3 In a second cohort…

How Prevalent Is Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica?

Colm Kirby, MB, BCh, BAO, MRCPI, Rachael Flood, MB, BCh, BAO, MRCPI, Ronan Mullan, MB, BCh, BAO, MRCPI, Grainne Murphy, MB, BCh, BAO, MRCPI, & David Kane, MB, BCh, BAO, MRCPI  |  January 24, 2024

Background/Purpose It has been reported that 20–50% of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). The natural history of ultrasound-defined subclinical GCA in PMR is not known. Methods Twenty-five newly diagnosed PMR patients who met a clinical diagnosis for PMR, verified by two rheumatologists, were examined by ultrasound. All six branches…

Study: Patients with PMR Experience Fatigue, Sleep Disturbance & Mood Disorders

Jessica Leung, MBBS, FRACP, Claire E. Owen, MBBS, PhD, FRACP, David Liew, MBBS, FRACP, & Russell Buchanan, MBBS, MD, FRACP  |  January 24, 2024

Background/Purpose Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients of additional symptoms, including fatigue and sleep disturbance. These features of PMR are less recognized by clinicians and have not yet been quantified in the literature. Further, the adequacy of…

How to Reduce Gout Flares

Keri Losavio  |  November 12, 2023

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

Immunology Insights for the Rheumatologist

Keri Losavio  |  October 10, 2023

The ACR journal, Arthritis & Rheumatology has introduced a new educational series, with the complement system first in focus. “This isn’t simplified immunology for trainees,” says Dr. Bucala. “It’s for everyone.”

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  September 11, 2023

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout

Arthritis Care & Research  |  August 13, 2023

Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…

Wired: Tech-Based Strategies for Engaging Patients in Research

Jason Liebowitz, MD, FACR  |  June 27, 2023

Artificial intelligence, social media, mobile apps—different technologies can be used to connect with and benefit rheumatology patients. During a session of the 2023 Pediatric Rheumatology Symposium, Dr. Jonathan Hausmann discussed the use of technology in research to improve patient recruitment and engagement, collect data and more.

Thick Skin & Solid Research: Necessary Ingredients for Publishing Success

Vanessa Caceres  |  June 1, 2023

Scientific publishing requires a commitment to clear writing, concise narratives and a willingness to accept feedback. Daniel Solomon, MD, editor-in-chief of Arthritis & Rheumatology, provides insights into his experiences.

RA Disease Activity & Alcohol Consumption Habits

Arthritis & Rheumatology  |  May 30, 2023

Past studies have suggested that patients with rheumatoid arthritis (RA) who consume a moderate amount of alcohol may experience lower disease activity and higher quality of life than non-drinkers. In this study, Alfredsson, et al. confirmed earlier studies’ claims that alcohol consumption reduces disease activity in a dose-dependent manner, and also indicated that patients who stopped drinking post-baseline experienced worsened disease activity, more pain and a lower quality of life.

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 126
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences